The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis

Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis

March 25, 2016 • By Rita Buckley

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found.

You Might Also Like
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Dr. Joy Tsai, from Massachusetts General Hospital in Boston, and colleagues conducted a single-site, two-year, open-label, randomized controlled trial involving 94 women aged 45 or older at high risk of fractures.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They randomized patients to 24 months of 20 mcg subcutaneous teriparatide daily, 60 mcg subcutaneous denosumab every six months or both.

Total volumetric bone mineral density (BMD) at the radius and tibia, trabecular volumetric BMD at the radius, and cortical volumetric BMD at the tibia increased more in the combination group compared with both monotherapy groups (p<0.002 for all comparisons to the combination).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Total volumetric BMD at the tibia increased by 4.2% compared with 2.6% for the monotherapy groups (p=0.001). At the radius, total volumetric BMD increased 3.3% (p<0.001) compared with 3.0% in the denosumab-only group and no change in the teriparatide group.

Cortical thickness at the tibia increased 8.1% in the combination group compared with 6.0% in the denosumab group (p<0.001) and no change in the teriparatide group.

Cortical porosity at both the radius and tibia increased progressively over 24 months of treatment in those taking teriparatide, but was stable in patients in both other groups (p<0.001 teriparatide versus both other groups).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Trabecular volumetric BMD at the tibia increased similarly in all groups, whereas radius trabecular volumetric BMD increased more in those on combination treatment compared with subjects in both monotherapy groups (p<0.01 for both comparisons).

Estimated stiffness and failure load showed similar increases in all groups at the tibia. Failure load increases at the tibia were larger in the combination group (p=0.045).

Finite element analysis-estimated strength at the radius and tibia improved or was maintained by all treatments. The researchers concluded that two years of combined teriparatide and denosumab improved bone microarchitecture and estimated strength more than individual treatments, especially in cortical bone.

“This study shows that combination treatment with denosumab and teriparatide results in favorable changes in bone quality at peripheral skeletal sites,” said Dr. Tsai told Reuters Health by email.

According to Dr. Bart L. Clarke, of the Mayo Clinic in Rochester, Minnesota, these findings are important.

“What makes this work valuable,” he told Reuters Health in a phone interview, “is that we’ve had few studies on combination therapy for osteoporosis.”

Dr. Clarke, who was not involved in the research, said that the outcomes invalidate a general assumption that absorptive agents shouldn’t be used in combination with teriparatide.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bone mineral density (BMD), combination therapy, denosumab, Osteoporosis, osteoporosis treatments, postmenopause, Women

You Might Also Like:
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.